Amarin Corporation plc

NASDAQ:AMRN

Biotechnology

Healthcare
$11.26 +1.84%

+$0.29 today

Market cap
$232.89M
Beta
0.82
P/E (TTM)
-9.9
EPS (TTM)
-$1.62
52W Low $12.30High $20.90

Volume 0.09M

Average 0.07M

AMRN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Amarin Corporation plcNASDAQ: AMRN

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 41.0%

Gross margin was 41.0% in Q1 FY2026, down 18.8 pp from a year earlier. On a trailing-twelve-month basis it was 52.5%, up 18.0 pp year over year. Over 3 fiscal years it narrowed by 9.1 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
41.0%-4.6 pp QoQ
Last fiscal yearDec 2025
56.6%+21.0 pp YoY
LTMMar 2026
52.5%+18.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-18.8 pp——
1 year+21.0 pp——
3 years-9.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
56.6%
Year-over-year change
+21.0pp

Gross Margin vs competitors

How AMRN compares with its peers on the latest reported figures

  • AMRN's LTM Mar 2026 gross margin of 52.5% is the 5th highest of the 7 companies compared; the peer median is 69.8%.
  • Its year-over-year change of +18.0 pp is the highest of 6, against a peer median of -26.8 pp.
  • Over three fiscal years its change of -9.1 pp compares with a peer median of +0.0 pp.
AMRN Competitors Peer median
Gross Margin for AMRN and competitors
Company Period LTM level YoY 3-year change
ACIUAC Immune S.A.LTM Mar 2026100.0% +0.0 pp+0.0 pp
CLLSCellectis S.A.LTM Mar 202681.9% +0.5 pp+30.8 pp
KRROKorro Bio, Inc.LTM Mar 202673.2% -26.8 pp—
SLNSilence Therapeutics plcLTM Mar 202666.4% —+23.7 pp
AMRNAmarin Corporation plcLTM Mar 202652.5% +18.0 pp-9.1 pp
LYELLyell Immunopharma, Inc.LTM Mar 2026-7422.6% -7522.6 pp-32052.8 pp
ALTAltimmune, Inc.LTM Mar 2026-41519.4% -41619.4 pp+0.0 pp
ANROAlto Neuroscience, Inc.FY2025— ——
LRMRLarimar Therapeutics, Inc.FY2025— ——
DBVTDBV Technologies S.A.FY2025— ——
ENGNenGene Holdings Inc.FY2025— ——
Peer median (excluding AMRN) 69.8%-26.8 pp+0.0 pp

Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue583.19M369.19M306.91M228.61M213.65M
Cost of Revenue121.33M126.71M141.37M147.23M92.78M
Gross Profit461.86M242.48M165.54M81.38M120.87M
Gross Margin79.2%65.7%53.9%35.6%56.6%
Research & Development29.31M30.41M22.22M20.87M19.81M
Selling, General & Admin408.33M304.42M199.94M152.31M115M
Operating Expenses451.36M348.35M222.16M173.18M134.81M
Depreciation & Amortization2.86M3.1M2.97M3.01M3.03M
EBITDA14.28M(100.69M)(50.7M)(74.18M)(33.01M)
EBITDA Margin2.4%-27.3%-16.5%-32.4%-15.5%
Operating Income10.5M(105.87M)(56.62M)(91.8M)(13.94M)
Operating Margin1.8%-28.7%-18.4%-40.2%-6.5%
Interest Income1.22M2.82M11.86M13.4M10.85M
Interest Expense129K15K8K7K7K
Other Income / Expenses789K2.06M2.95M14.6M(22.11M)
Income Before Tax11.29M(103.81M)(53.67M)(77.2M)(36.05M)
Pre-Tax Margin1.9%-28.1%-17.5%-33.8%-16.9%
Income Tax Expense3.56M2M5.44M4.98M2.75M
Net Income7.73M(105.8M)(59.11M)(82.18M)(38.8M)
Net Margin1.3%-28.7%-19.3%-35.9%-18.2%
EPS (Basic)0.39(5.20)(3.00)(4.00)(1.80)
EPS (Diluted)0.38(5.20)(3.00)(4.00)(1.80)
Weighted Avg Shares19.8M20.06M19.7M20.55M20.75M
Weighted Avg Shares (Diluted)20.12M20.06M20.38M20.55M20.75M

Amarin Corporation plc

NASDAQ:AMRN

Intrinsic Alpha fair value

Locked

Current Price

$11.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.